SYMBIOTEC · NSE
Symbiotec Pharmalab Limited
₹1,095.1
+4.73% (+₹49.5)
Prev. close
₹1,045.6
Volume
10,99,366
Delivery %
35.8%
As of
18 Sept 2026
Price history
Analyst sentiment
Analysts lean bullish
2 analyst stances · last 90 days · one per analyst
Trackable
none in window
Long-Horizon
none in window
Commentary
2 · 2 bull / 0 neutral / 0 bear
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
Market commentary · 2 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Recommended 'Subscribe' to the Symbiotec Pharmalab IPO, considering the issue's valuation at a FY26 P/E multiple of 54.6…” | SBI Securities AnalysisSBI Securities | Symbiotec Pharmalab | PENDING | |
| “Bullish on Symbiotec Pharmalab IPO, assigning an 'apply' tag due to its integrated pharmaceutical and biotechnology plat…” | Mahesh M OjhaKantilal Chaganlal Securities | Symbiotec Pharmalab | PENDING |
Fundamentals
About Symbiotec Pharmalab Limited
Symbiotec Pharma Lab Pvt. Ltd. develops, manufactures, and markets active pharmaceutical ingredients (APIs), with a primary focus on cortico-steroids and steroid-hormone APIs in both sterile and non-sterile forms. The company synthesizes progestin, estrone, testosterone, their derivatives, and anabolic steroids, supplying these in commercial volumes globally. It offers APIs and intermediate pharmaceutical products for therapeutic areas such as gastrointestinal ailments, cardiovascular disease, pain management, paediatrics, anti-infective, and dermatology. The company provides contract manufacturing (CMO) and contract development and manufacturing (CDMO) services, particularly for fermentation-based APIs, and operates large-scale manufacturing facilities with dedicated research and development and quality control laboratories. Its product portfolio includes APIs outside the cortico-steroids and hormone categories, with several products under development. The company serves clients in the pharmaceutical industry, including organizations involved in pharmaceutical manufacturing, contract manufacturing, and research and development, as well as global pharmaceutical companies. The company was founded in 2002 and is based in Indore, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. Anil Satwani
Headquarters
Indore
Employees
1,752
Website
symbiotec.comExchange
View on NSE ↗Key stats
Market cap
₹6,718.62 Cr
P/E ratio (TTM)
63.9
EPS (TTM)
₹17.15
Shares float
2.54 Cr
EPS · quarter ended Jun 2025
₹4.66
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹545.78 Cr | ₹716.25 Cr | ₹751.55 Cr | ₹869.15 Cr | |
| EBITDA | ₹72.17 Cr | ₹177.04 Cr | ₹206.11 Cr | ₹231.97 Cr |
| ₹23.47 Cr | ₹100.18 Cr | ₹96.78 Cr | ₹109.88 Cr | |
| Diluted EPS | ₹3.65 | ₹15.59 | ₹15.06 | — |
Diluted EPS has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹989.99 Cr | ₹1,294.79 Cr | ₹1,579.65 Cr | ₹1,780.79 Cr | |
| ₹219.96 Cr | ₹250.60 Cr | ₹544.44 Cr | ₹390.99 Cr | |
| Stockholders' equity | ₹621.53 Cr | ₹715.05 Cr | ₹814.89 Cr | ₹1,149.73 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹69.24 Cr | ₹187.50 Cr | ₹47.26 Cr | ₹174.59 Cr | |
| Investing cash flow | ₹-219.99 Cr | ₹-206.41 Cr | ₹-306.52 Cr | ₹-226.93 Cr |
| ₹146.14 Cr | ₹21.85 Cr | ₹278.16 Cr | ₹35.99 Cr | |
| Capital expenditure | ₹-224.39 Cr | ₹-209.77 Cr | ₹-308.12 Cr | ₹-225.72 Cr |
| End cash position | ₹4.55 Cr | ₹7.50 Cr | ₹26.39 Cr | ₹10.04 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Aug 26 |
|---|---|
| Promoter | 33.28% |
| Public | 66.72% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Symbiotec Pharmalab Limited | ₹7,293.39 Cr | ₹1,133.45 | 66.3 | 6.34 | 9.6% | 0.34 | +15.6% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
2 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.